You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for aTAG 4531
aTAG 4531 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.34 nM; Dmax = 93.14%). Cell-permeable. Suitable for in vitro and in vivo applications.
Mouse DMPK properties are provided in the supplementary file (see below).
MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.
Sold under license from C4 Therapeutics
Mouse DMPK properties are provided in the accompanying supplementary file.
Technical Data for aTAG 4531
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for aTAG 4531
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for aTAG 4531
The following data is based on the product molecular weight 867.85. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.52 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
References for aTAG 4531
References are publications that support the biological activity of the product.
If you know of a relevant reference for aTAG 4531, please let us know.
View Related Products by Target
Keywords: aTAG 4531, aTAG 4531 supplier, aTAG4531, CFT4531, atag, Achilles, heel, degraders, degradation, MTH1, fusion, protein, PROTAC, proteolysis, targeting, chimeras, targeted, TPD, CFT, 4531, TAG, Degradation, Platform, 6971, Tocris Bioscience
Citations for aTAG 4531
Citations are publications that use Tocris products.
Currently there are no citations for aTAG 4531. Do you know of a great paper that uses aTAG 4531 from Tocris? Please let us know.
Reviews for aTAG 4531
There are currently no reviews for this product. Be the first to review aTAG 4531 and earn rewards!
Have you used aTAG 4531?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Protocols for aTAG 4531
The following protocol features additional information for the use of aTAG 4531 (Cat. No. 6971).
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Targeted Protein Degradation Research Product Guide
This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:
- Active Degraders
- Degrader Building Blocks
- Custom Degrader Services
- UPS Proteins and Assays
- Assays for Protein Degradation
Targeted Protein Degradation Poster
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia